Amgen Inc. (AMGN) Holdings Lifted by James Investment Research Inc.
James Investment Research Inc. raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 35.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,280 shares of the medical research company’s stock after buying an additional 3,760 shares during the period. James Investment Research Inc.’s holdings in Amgen were worth $2,459,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in the business. Bank of New York Mellon Corp boosted its position in shares of Amgen by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company’s stock valued at $1,403,676,000 after buying an additional 195,200 shares during the period. Schwab Charles Investment Management Inc. boosted its position in shares of Amgen by 1.6% during the first quarter. Schwab Charles Investment Management Inc. now owns 2,894,780 shares of the medical research company’s stock valued at $474,947,000 after buying an additional 45,403 shares during the period. UBS Asset Management Americas Inc. boosted its position in shares of Amgen by 3.1% during the first quarter. UBS Asset Management Americas Inc. now owns 2,719,874 shares of the medical research company’s stock valued at $446,250,000 after buying an additional 81,362 shares during the period. Swiss National Bank boosted its position in shares of Amgen by 26.5% during the first quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock valued at $432,490,000 after buying an additional 551,600 shares during the period. Finally, Ameriprise Financial Inc. boosted its position in shares of Amgen by 0.7% during the first quarter. Ameriprise Financial Inc. now owns 1,479,687 shares of the medical research company’s stock valued at $242,555,000 after buying an additional 10,109 shares during the period. Institutional investors and hedge funds own 78.10% of the company’s stock.
Several brokerages have issued reports on AMGN. UBS AG restated a “neutral” rating and set a $175.00 target price (up previously from $174.00) on shares of Amgen in a research report on Tuesday, June 13th. Bank of America Corporation boosted their target price on Amgen to $210.00 and gave the company a “buy” rating in a research report on Thursday. Morgan Stanley boosted their target price on Amgen from $189.00 to $196.00 and gave the company an “overweight” rating in a research report on Friday. Mizuho restated a “buy” rating and set a $198.00 target price on shares of Amgen in a research report on Friday. Finally, Cann restated a “buy” rating and set a $203.00 target price on shares of Amgen in a research report on Friday. Ten analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $189.99.
Shares of Amgen Inc. (NASDAQ:AMGN) traded down 0.64% during trading on Friday, hitting $185.66. The stock had a trading volume of 880,649 shares. The stock’s 50 day moving average price is $180.82 and its 200-day moving average price is $170.11. The stock has a market cap of $135.47 billion, a P/E ratio of 16.91 and a beta of 1.36. Amgen Inc. has a one year low of $133.64 and a one year high of $191.10. Amgen also saw some unusual options trading activity on Thursday. Stock investors bought 9,350 put options on the stock. This is an increase of approximately 239% compared to the typical volume of 2,758 put options.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. During the same period last year, the business earned $2.84 EPS. The company’s revenue was up 2.1% on a year-over-year basis. Analysts expect that Amgen Inc. will post $12.58 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were issued a $1.15 dividend. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.46%. Amgen’s payout ratio is 41.93%.
ILLEGAL ACTIVITY NOTICE: “Amgen Inc. (AMGN) Holdings Lifted by James Investment Research Inc.” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/amgen-inc-amgn-holdings-lifted-by-james-investment-research-inc/1613286.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.